Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Attention Deficit Hyperactivity Disorder
Sciele and Addrenex Announce NDA Submission of CloniBID to Treat Hypertension
March 7th, 2008
Sciele Pharma, Inc. (NASDAQ:SCRX) and Addrenex Pharmaceuticals, Inc. announced that Addrenex has submitted a 505(b)(2) New Drug Application (NDA) to the Federal Food & Drug Administration (FDA) for CloniBID for the treatment of hypertension. Upon FDA approval, Sciele expects to launch this product in the first half of 2009. In June 2007, the Company licensed CloniBID and Clonicel from Addrenex Pharmaceuticals; CloniBID for the treatment of hypertension and Clonicel for the treatment of attention deficit/hyperactivity disorder (ADHD). CloniBID and Clonicel are both 12-hour, sustained-release formulations of clonidine hydrochloride. Both products will include a new...
Source: Health Business Week (2008-03-07)
|
